274 related articles for article (PubMed ID: 11074355)
1. Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat.
Martel C; Picard S; Richard V; Bélanger A; Labrie C; Labrie F
J Steroid Biochem Mol Biol; 2000 Sep; 74(1-2):45-56. PubMed ID: 11074355
[TBL] [Abstract][Full Text] [Related]
2. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
Armamento-Villareal R; Sheikh S; Nawaz A; Napoli N; Mueller C; Halstead LR; Brodt MD; Silva MJ; Galbiati E; Caruso PL; Civelli M; Civitelli R
J Bone Miner Res; 2005 Dec; 20(12):2178-88. PubMed ID: 16294271
[TBL] [Abstract][Full Text] [Related]
3. Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.
Sutherland MK; Brady H; Gayo-Fung LM; Leisten J; Lipps SG; McKie JA; O'Leary E; Patnaik N; Anderson DW; Bhagwat SS; Stein B
Calcif Tissue Int; 2003 Jun; 72(6):710-6. PubMed ID: 14563000
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.
Ke HZ; Chen HK; Simmons HA; Qi H; Crawford DT; Pirie CM; Chidsey-Frink KL; Ma YF; Jee WS; Thompson DD
Bone; 1997 Jan; 20(1):31-9. PubMed ID: 8988345
[TBL] [Abstract][Full Text] [Related]
5. Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat.
Martel C; Sourla A; Pelletier G; Labrie C; Fournier M; Picard S; Li S; Stojanovic M; Labrie F
J Endocrinol; 1998 Jun; 157(3):433-42. PubMed ID: 9691976
[TBL] [Abstract][Full Text] [Related]
6. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
[TBL] [Abstract][Full Text] [Related]
7. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
Black LJ; Sato M; Rowley ER; Magee DE; Bekele A; Williams DC; Cullinan GJ; Bendele R; Kauffman RF; Bensch WR
J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823
[TBL] [Abstract][Full Text] [Related]
8. The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats.
Goss PE; Qi S; Cheung AM; Hu H; Mendes M; Pritzker KP
J Steroid Biochem Mol Biol; 2004 Sep; 92(1-2):79-87. PubMed ID: 15544933
[TBL] [Abstract][Full Text] [Related]
9. Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH.
Iwaniec UT; Samnegård E; Cullen DM; Kimmel DB
Bone; 2001 Oct; 29(4):352-60. PubMed ID: 11595618
[TBL] [Abstract][Full Text] [Related]
10. Effect of ormeloxifene on ovariectomy-induced bone resorption, osteoclast differentiation and apoptosis and TGF beta-3 expression.
Narayana Murthy PS; Sengupta S; Sharma S; Singh MM
J Steroid Biochem Mol Biol; 2006 Aug; 100(4-5):117-28. PubMed ID: 16797179
[TBL] [Abstract][Full Text] [Related]
11. The preventive and interventional effects of raloxifene analog (LY117018 HCL) on osteopenia in ovariectomized rats.
Li X; Takahashi M; Kushida K; Inoue T
J Bone Miner Res; 1998 Jun; 13(6):1005-10. PubMed ID: 9626632
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats.
Ma YL; Bryant HU; Zeng Q; Schmidt A; Jee WS; Sato M
J Bone Miner Metab; 2005; 23 Suppl():62-8. PubMed ID: 15984416
[TBL] [Abstract][Full Text] [Related]
13. Effects of tibolone (Org OD14) treatment for 3 months on ovariectomy-induced osteopenia in 8-month-old rats on a low-calcium diet: preventive testing for 3 months.
Kasugai Y; Ikegami A; Matsuo K; Ohashi M; Sukamoto T; Hosoi T; Ouchi Y; Orimo H
Bone; 1998 Feb; 22(2):119-24. PubMed ID: 9477234
[TBL] [Abstract][Full Text] [Related]
14. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.
Ke HZ; Chen HK; Qi H; Pirie CM; Simmons HA; Ma YF; Jee WS; Thompson DD
Bone; 1995 Nov; 17(5):491-6. PubMed ID: 8579962
[TBL] [Abstract][Full Text] [Related]
15. Effects of the selective estrogen receptor modulator ospemifene on bone in rats.
Kangas L; Härkönen P; Väänänen K; Peng Z
Horm Metab Res; 2014 Jan; 46(1):27-35. PubMed ID: 24108389
[TBL] [Abstract][Full Text] [Related]
16. The new selective estrogen receptor modulator MDL 103,323 increases bone mineral density and bone strength in adult ovariectomized rats.
Ammann P; Bourrin S; Bonjour JP; Brunner F; Meyer JM; Rizzoli R
Osteoporos Int; 1999; 10(5):369-76. PubMed ID: 10591834
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251
[TBL] [Abstract][Full Text] [Related]
18. Raloxifene and vitamin K2 combine to improve the femoral neck strength of ovariectomized rats.
Iwamoto J; Yeh JK; Schmidt A; Rowley E; Stanfield L; Takeda T; Sato M
Calcif Tissue Int; 2005 Aug; 77(2):119-26. PubMed ID: 16059775
[TBL] [Abstract][Full Text] [Related]
19. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.
Sato M; Turner CH; Wang T; Adrian MD; Rowley E; Bryant HU
J Pharmacol Exp Ther; 1998 Oct; 287(1):1-7. PubMed ID: 9765314
[TBL] [Abstract][Full Text] [Related]
20. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.
Ke HZ; Simmons HA; Pirie CM; Crawford DT; Thompson DD
Endocrinology; 1995 Jun; 136(6):2435-41. PubMed ID: 7750465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
